Wellington Management Group LLP Makes New Investment in Celcuity Inc. (NASDAQ:CELC)

Wellington Management Group LLP acquired a new position in Celcuity Inc. (NASDAQ:CELC) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 51,611 shares of the company’s stock, valued at approximately $770,000. Wellington Management Group LLP owned approximately 0.14% of Celcuity at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. State Street Corp boosted its holdings in Celcuity by 152.2% in the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company’s stock worth $16,512,000 after buying an additional 668,318 shares during the period. Braidwell LP boosted its stake in shares of Celcuity by 71.2% in the third quarter. Braidwell LP now owns 884,306 shares of the company’s stock worth $13,185,000 after acquiring an additional 367,663 shares during the period. Acuta Capital Partners LLC grew its position in shares of Celcuity by 3.6% during the third quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock worth $695,000 after purchasing an additional 1,600 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Celcuity by 2,083.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company’s stock valued at $673,000 after purchasing an additional 43,044 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Celcuity by 226.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 221,671 shares of the company’s stock worth $3,305,000 after purchasing an additional 153,712 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Celcuity in a report on Friday, November 15th. Lifesci Capital initiated coverage on shares of Celcuity in a report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th. Finally, Stifel Nicolaus lifted their target price on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $29.17.

Celcuity Stock Down 0.8 %

Shares of NASDAQ:CELC opened at $12.00 on Friday. The company has a market cap of $445.56 million, a price-to-earnings ratio of -4.60 and a beta of 0.74. Celcuity Inc. has a 12 month low of $11.51 and a 12 month high of $22.19. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average price of $14.14 and a 200 day moving average price of $15.40.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.